Official Title
A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia
Brief Summary

The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).

Status
Completed
Conditions
COVID
Interventions

Biological: avdoralimab

intravenous administration of avdoralimab
Other Name: IPH5401

Other: Placebo

intravenous administration of placebo

Eligibility Criteria

Inclusion Criteria:

- COVID-19 severe pneumonia patients need for oxygen therapy ≥ 5 l/min or high-flow
oxygen therapy

- COVID-19 related Acute Respiratory Distress Syndrome (ARDS) requiring mechanical
ventilation

Exclusion Criteria:

- Pregnant woman

- Uncontrolled sepsis of bacterial or fungal origin

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 80 Years
Countries
France
Locations

Assistance Publique Hôpitaux de Marseille
Marseille, France

Investigators

Emilie Garrido-Pradalie, Study Director
Assistance Publique Hôpitaux de Marseille

Sponsors / Collaborators
Innate Pharma
NCT Number
NCT04371367
MeSH Terms
Pneumonia
Avdoralimab